Skip to main content

Table 1 Baseline characteristics according to acute kidney injury

From: Impact of acute kidney injury on survival in patients with chronic hepatitis C: a retrospective cohort study

  All patients (n = 1252) AKI (n = 285) No AKI (n = 967)
Age, year a 58.0 (49.0–67.8) 65.0 (54.0–71.0) 57.0 (48.0–66.0)
Male sexa 685 (54.7%) 176 (61.8%) 509 (52.6%)
Hypertension a 321 (25.6%) 112 (39.3%) 209 (21.6%)
Diabetes a 286 (22.8%) 108 (37.9%) 178 (18.4%)
Alcohol > 40 g/day 244 (19.5%) 65 (22.8%) 179 (18.5%)
Diagnosis at entry a
 CH 1008 (80.5%) 186 (18.5%) 822 (81.5%)
 Com-LC 123 (9.8%) 34 (27.6%) 89 (72.4%)
 Decom-LC or HCC 121 (9.7%) 65 (53.7%) 56 (46.3%)
Genotype
 1 545 (43.5%) 108 (37.9%) 437 (45.2%)
 2 603 (48.2%) 150 (52.6%) 453 (46.8%)
 3 101 (8.1%) 26 (9.1%) 75 (7.8%)
 Others 3 (0.2%) 1 (0.4%) 2 (0.2%)
Extrahepatic malignancy a 90 (7.2%) 35 (12.3%) 55 (5.7%)
SVR a 606 (48.4%) 49 (17.2%) 557 (57.7%)
HCV RNA > 600,000 IU/mL 202 (16.1%) 42 (14.7%) 160 (16.5%)
Albumin, g/dL a 4.1 (3.7–4.4) 3.7 (3.1–4.1) 4.2 (3.9–4.5)
Bilirubin, mg/dL a 0.69 (0.50–1.00) 0.77 (0.50–1.25) 0.67 (0.50–0.94)
Platelet, ×109/L a 183.0 (131.0–232.0) 151.0 (102.0–215.0) 190.0 (142.0–233.0)
PT-INR a 1.03 (0.99–1.11) 1.09 (1.02–1.22) 1.01 (0.98–1.09)
Child-Pugh B or C at entry a 112 (8.9%) 66 (58.9%) 46 (41.1%)
MELD score at entry a 7.0 (6.0–8.0) 8.0 (7.0–10.0) 7.0 (6.0–8.0)
Follow-up period (year) 4.2 (2.1–7.9) 4.6 (2.1–8.0) 4.1 (2.0–7.8)
  1. Data are presented as median (interquartile range) for continuous data and percentages for categorical data
  2. Abbreviations: CH Chronic hepatitis, Com-LC Compensated cirrhosis, Decom-LC Decompensated cirrhosis, HCC Hepatocellular carcinoma, SVR Sustained virologic response, HCV Hepatitis C virus, PT-INR Prothrombin time-international normalized ratio, MELD score Model For End-Stage Liver Disease score
  3. a p < 0.05 AKI vs No AKI using the Mann-Whitney U test and Chi-squared test